Highlights include the company’s strong foundation for growth, focus on innovation and attractive long-term outlookSAN DIEGO, Sept. 29, 2023 (GLOBE…
ISELIN, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve FDA…
Akari’s priority pipeline programs remain on track to begin enrollment in the registrational nomacopan Phase 3 clinical trials in pediatric…
NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative…
EDISON, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on artificial…
TEL AVIV, Israel, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical…
$300 million financing includes significant participation from a number of large healthcare dedicated institutional and mutual fund investors Net proceeds,…
GSBR-1290 shown to be generally well-tolerated with no adverse event-related discontinuations in Phase 1b multiple ascending dose study Significant weight…
Stephen Dilly Headshot Stephen Dilly, MBBS, PhD, President & CEO of Codexis, Inc.REDWOOD CITY, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE)…
SEATTLE, Sept. 29, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on development of targeted inhalation…